Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who Will Join Us? EU Regulators Seek Feedback On Proposed Clinical Trials Discussion Platform

Executive Summary

Regulators want to know who is interested in joining their planned multi-stakeholder platform for discussions on how to improve clinical trials in Europe. They are also seeking feedback on which topics should be prioritized for discussion.

You may also be interested in...



EU To Consult On Plans For Holistic Dialog On Clinical Trials

EU regulators will soon be inviting feedback on plans to establish a keenly awaited platform that would allow EU clinical trial stakeholders to undertake regular discussions on improving the research landscape.

EMA Report Highlights Parallel Regulatory/HTA Consultations Among Achievements

A report from the EMA summarizing the mid-term achievements of its Regulatory Science Strategy to 2025 covers health technology assessments and a range of other topics.

Upstaza: First Gene Therapy For Ultra-Rare Disorder AADC Deficiency Receives English Funding

The single-dose gene therapy for aromatic L-amino acid decarboxylase in children is to be made available on the National Health Service following a confidential commercial deal between NHS England and PTC Therapeutics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel